Cytokinetics (CYTK) Form 144: Proposed 6,756-Share Sale Disclosed
Rhea-AI Filing Summary
Cytokinetics, Inc. (CYTK) Form 144 notice reports a proposed sale of 6,756 common shares through Morgan Stanley Smith Barney, with an aggregate market value of $238,689.48 based on the filing. The filing lists 119,657,156 shares outstanding and an approximate sale date of 09/02/2025. The shares to be sold were acquired as Restricted Stock Units on 01/03/2022 and payment is marked N/A. The filer also disclosed 10b5-1 sales by Edward Kaye of 3,636 shares on 06/05/2025 for $116,714.87. The document contains standard Rule 144 attestations and a signature block; no relationship to the issuer or additional context is provided in the filing.
Positive
- None.
Negative
- None.
Insights
TL;DR: Routine Rule 144 disclosure of a small planned insider sale, with prior 10b5-1 sales also disclosed.
The filing documents a proposed sale under Rule 144 of 6,756 common shares via Morgan Stanley Smith Barney, acquired as RSUs on 01/03/2022. It includes a prior 10b5-1 sale by Edward Kaye of 3,636 shares on 06/05/2025 for $116,714.87. This is a standard regulatory notification ensuring public disclosure of insider sales and planned sales; the filing contains the required attestations but does not provide additional material company information.
TL;DR: Disclosure is compliant and routine; the transactions disclosed are small relative to outstanding shares.
The notice shows the shares were RSUs granted by the issuer and that the seller relies on Rule 144 for the proposed sale dated 09/02/2025. The filing properly lists broker, quantity, and aggregate value and discloses recent 10b5-1 activity. There is no evidence in this document of material corporate developments or governance events beyond normal insider share disposition reporting.